Mark Prausnitz, Ph.D.
Chief Scientific Officer and Co-Founder

Dr. Prausnitz has served as Micron’s Chief Scientific Officer since its inception and is a co-founder of the company.  Dr. Prausnitz is Regents’ Professor of Chemical and Biomedical Engineering at the Georgia Institute of Technology. He has carried out research on drug delivery systems for more than 25 years and has co-founded four companies. Dr. Prausnitz received a BS degree from Stanford University and a PhD from MIT, both in chemical engineering.

He has published almost 240 research articles, about half of which are on microneedles, and has more than 30 US patents issued or pending. Dr. Prausnitz has raised more than $30 million in funding for microneedles research at Georgia Tech. He has consulted for dozens of companies, mostly on the subject of microneedles.

Devin-1-234x300 (1)

Devin McAllister, Ph.D.
Vice President, Research & Development and Co-Founder

Dr. McAllister has served as Micron’s Vice President, Research & Development since its inception and is a co-founder of the company. Dr. McAllister has almost 20 years of experience developing medical devices and pharmaceutical dosage forms including microneedle patch technologies. He received a BS from Rensselaer Polytechnic Institute and a PhD from the Georgia Institute of Technology, both in chemical engineering. Dr. McAllister led the process development and GMP manufacturing efforts on Georgia Tech’s NIH-funded project on the development of a microneedle patch for influenza vaccination that was studied in a phase 1 clinical trial in 2015-2016 and is currently in charge of Micron’s R&D activities, overseeing the development of Micron’s microneedle patch technology and serving as the principal investigator on several grants and contracts including from the Gates Foundation and the CDC.

Previously, Dr. McAllister was the technical head of Valeritas’ microneedle development program. He is also a co-inventor of V-Go, the first insulin pump marketed to the large Type 2 diabetes market. He has over 30 US patents issued or pending and has served as a consultant for a number of medical device companies. Prior to Valeritas, he was a Senior R&D Engineer at Johnson & Johnson.


Sebastien Henry, MS, MBA
Vice President, Program Management and Co-Founder

Mr. Henry has served as Micron’s Vice President, Program Management since its inception and is a co-founder of the company. Mr. Henry has over 15 years of research, product development and project management experience in the microneedle and medical device fields including overall product development responsibilities at Porex Surgical, now owned by Stryker, a company that develops, manufactures, and sells craniofacial implants to surgeons in five surgical specialties.

He received a BS from the University of Technology of Compiègne (France) and an MS from the Georgia Institute of Technology, both in bioengineering, as well as an MBA from the Georgia Institute of Technology. Mr. Henry has 8 US patents issued or pending and has worked on microneedles projects at Georgia Tech and Micron for over 10 years.

Micron develops pharmaceutical products, based on its microneedle patch technology, that are designed to provide enhanced protective (vaccine) and therapeutic (drugs) effects, superior patient compliance, and simplified administration, distribution, and storage logistics.


Phase 1 clinical trial shows safety and immunogenicity of microneedle patch for flu vaccination for the first time

(GLOBE NEWSWIRE) — Using microneedle patch technology under development at Micron Biomedical, Inc. (Micron), a Phase 1 clinical trial showed that vaccination by microneedle patch was as safe and at least as immunogenic as vaccination with standard needle and syringe. The trial was carried out by the Georgia Institute of Technology (Georgia Tech) and the…

Micron to collaborate with Georgia Tech and CDC on measles-rubella project funded by UNICEF

ATLANTA, June 19, 2017 – UNICEF awards funding to support to work of Micron Biomedical, Inc. to develop cGMP manufacturing for a measles-rubella (MR) vaccine microneedle patch, to design and support pre-clinical studies, and to develop the regulatory strategy, including IND preparation, to support a future Phase 1/2a clinical trial and, ultimately, to obtain licensure…

Micron invited to participate in the BIO 2017 conference Innovation Zone

ATLANTA, April 12, 2017 – Micron Biomedical, Inc. was selected by NIH to participate in the BIO 2017 conference in San Diego, CA, June 19-22, 2017 and to exhibit in the Innovation Zone, an exhibit space dedicated to showcasing a small number of NIH SBIR/STTR awardees.  Micron was also selected to give a presentation on…